Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.

The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5a and R.sup.5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.

##STR00001##

There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

The synthesis of various pyrazino[1,2:1,5]pyrrolo[2,3-B]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-a or Formula I-b: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, are provided herein. These biologically active derivatives have been used to effectively treat various diseases including cancer.

The synthesis of various pyrazino[1,2:1,5]pyrrolo[2,3-B]-indole-1,4-dione analogs has been successfully implemented in the present application. From these efforts, compounds having the structure of Formula I-a or Formula I-b: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, are provided herein. These biologically active derivatives have been used to effectively treat various diseases including cancer.

The present invention relates to tripeptide compounds according to the general formula (1) and their use as a medicament, in particular as anti-inflammatory agents. ##STR00001##

Provided herein are mertansine polypeptide conjugates useful in the treatment of cancer, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The methods provided herein are highly N-terminal selective and are capable of yielding N-terminal mertansine conjugated polypeptides with site selectivity of 99% or greater.

Provided herein are mertansine polypeptide conjugates useful in the treatment of cancer, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The methods provided herein are highly N-terminal selective and are capable of yielding N-terminal mertansine conjugated polypeptides with site selectivity of 99% or greater.

The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (CHP).

The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (CHP).